ARTICLE | Finance

Building a British Shield

Why Switzerland's Shield Therapeutics is looking to list on the LSE

September 21, 2015 7:00 AM UTC

A London Stock Exchange IPO next month would complete Shield Therapeutics AG's transition from Switzerland to the U.K. by putting the biotech under a U.K. holding company.

CEO Carl Sterritt told BioCentury that when he co-founded Shield in 2008, the company opted to incorporate in Switzerland because "we thought the corporate tax situation was more beneficial for our shareholders than being a U.K.-based company." ...